Chandorkar A G, Burte N P, Gade R K, Bulakh P M
Indian J Lepr. 1984 Jan-Mar;56(1):63-70.
The therapeutic effect of rifampicin 1200 mg once monthly and 100 mg clofazimine daily for the first six months of treatment was evaluated in 30 patients of bacteriologically positive lepromatous leprosy patients. Moderate to marked clinical improvement was seen in all the patients and a very rapid bacteriological regression as indicated by the decrease in bacteriological and morphological indices of the skin within one week. Seven patients become MI negative at one month and three months and 13 at the end of nine months. Two patients became MI and BI negative at the end of six months and six at the end of nine months. These observations clearly establish the high therapeutic efficacy and practicability of the three drug regimen. Once monthly rifampicin is highly effective and well tolerated, and has many advantages like low cost, better patient compliance and reliability of the treatment. Addition of clofazimine to rifampicin and dapsone prevents the emergence of E.N.L. reactions which were seen during treatment with once monthly rifampicin and daily dapsone. This regimen is thus ideal for initial, intensive treatment of lepromatous leprosy and may help in preventing the spread of the disease and development of dapsone resistance.
对30例细菌学检查阳性的瘤型麻风患者，评估了每月1次服用1200 mg利福平及治疗前6个月每日服用100 mg氯法齐明的治疗效果。所有患者均出现中度至显著的临床改善，且细菌学指标迅速下降，表明在1周内皮肤的细菌学和形态学指标有所降低。7例患者在1个月和3个月时MI转为阴性，9个月末13例转为阴性。2例患者在6个月末MI和BI转为阴性，9个月末6例转为阴性。这些观察结果清楚地证实了三联药物疗法具有很高的治疗效果和实用性。每月1次服用利福平高效且耐受性良好，具有低成本、患者依从性更好以及治疗可靠性高等诸多优点。在利福平和氨苯砜中加入氯法齐明可预防在每月1次服用利福平和每日服用氨苯砜治疗期间出现的ENL反应。因此，该疗法是瘤型麻风初始强化治疗的理想选择，可能有助于预防疾病传播和氨苯砜耐药性的产生。
